Abstract: The invention relates to vaccine compositions for inducing an immune response to a coronavirus in a subject, and uses thereof. In particular, the vaccine comprises of a chimeric or fusion protein comprising a) a N-terminal secretion signal peptide; b) an amino acid sequence of the receptor binding domain (RBD) of a spike protein of a coronavirus; and c) a C-terminal domain comprising a transmembrane region and a cytoplasmic region. In a preferred embodiment, the signal peptide, RBD, transmembrane region, and cytoplasmic region are derived from SARS-CoV-2, and that the vaccine composition is formulated as a lipid nanoparticle (LNP).

Abstract: This invention relates to berberine alkaloids, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals, particularly Lawsonia infection. In particular, the invention relates to berberine alkaloids, formulations thereof, and their application as antimicrobial agents in the prevention and/or treatment of infectious disease including bacterial, viral, parasitic or fungal infections, and for improving feed conversion ratio in food-producing animals. Also described is the use of berberine alkaloids as feed preservatives, added to feed compositions, and used in combination with further agents suitable for treating infectious disease.

Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Abstract: The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.

Abstract: This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease in animals.

Abstract: This invention relates to berberine alkaloids, formulations thereof and their use for the prevention and/or treatment of infectious disease, especially disease caused by C. perfringens and Eimeria in animals. The invention also relates to improving the feed conversion ratio in a food producing animal by administering berberine compositions.

Abstract: Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.

Abstract: This invention relates to berberine alkaloids, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals, particularly Lawsonia infection. In particular, the invention relates to berberine alkaloids, formulations thereof, and their application as antimicrobial agents in the prevention and/or treatment of infectious disease including bacterial, viral, parasitic or fungal infections, and for improving feed conversion ratio in food-producing animals. Also described is the use of berberine alkaloids as feed preservatives, added to feed compositions, and used in combination with further agents suitable for treating infectious disease.

Abstract: The disclosure relates to nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals. In particular, the disclosure relates to 5-nitroimidazoles and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease in animals including bacterial, viral, parasitic or fungal infections. More particularly, the invention relates to metronidazole and related compounds and derivatives, formulations thereof, and their use in the prevention and/or treatment of infectious disease caused by Clostridium species. Most preferably, the nitroimidazole is metronidazole administered in combination with berberine, or a berberine alkaloid, in a synergistic weight ratio of 1:1 or 1:2.

Abstract: Non-viral nucleic acid delivery agents and methods for the delivery or transfer of nucleic acid molecules to target cells are disclosed. The agents comprise a complex of a nucleic acid cargo for delivery, one or more lipopeptide compound, and one or more polymeric charge-neutralising agent, and the complex is in the form of a particle with substantially neutral or negative surface charge. The agents and methods may be useful in a variety of applications such as therapies (including gene therapies and nucleic acid vaccinations) for diseases and medical disorders.

Abstract: A device is provided which is suitable for delivering at least one nanoparticle(s) to a subject. The device can be used to deliver a variety of nanoparticles, for example, therapeutic agents, directly through the outer layers of the skin without passing completely through the epidermis of the subject. Thus the device can be used to deliver therapeutic agents to a predetermined depth and avoid disturbing the pain receptors in the skin. Thus the device can be used to deliver agents, including therapeutic agents, in a non-invasive manner. A method of fabricating devices with associated nanoparticles is also provided.

Abstract: A device is provided which is suitable for delivering at least one nanoparticle(s) to a subject. The device can be used to deliver a variety of nanoparticles, for example, therapeutic agents, directly through the outer layers of the skin without passing completely through the epidermis of the subject. Thus the device can be used to deliver therapeutic agents to a predetermined depth and avoid disturbing the pain receptors in the skin. Thus the device can be used to deliver agents, including therapeutic agents, in a non-invasive manner. A method of fabricating devices with associated nanoparticles is also provided.